Patents by Inventor Shoukath M. Ali
Shoukath M. Ali has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240115525Abstract: A method for managing or decreasing a risk of adverse effects in a patient undergoing treatment of bipolar I disorder is provided. The said method includes maintaining the therapeutically effective concentration of endoxifen by administrating a dose of 2 mg to 16 mg of endoxifen citrate in an enteric coated tablet once per day for at least 21 days. Further, adverse effects of alteration in thyroid functions, and thrombocytopenia can be avoided.Type: ApplicationFiled: December 19, 2023Publication date: April 11, 2024Inventors: Ateeq AHMAD, Imran AHMAD, Moghisuddin AHMAD, Shoukath M ALI, Saifuddin SHEIKH
-
Patent number: 11672758Abstract: The present invention provides compositions containing endoxifen, formulations and liposomes of endoxifen, methods of preparation of such agents and formulations, and use of such agents and formulations for the treatment of a subject having or at risk for psychiatric and neurodegenerative diseases. Specifically, the present invention relates to the composition comprising endoxifen in the treatment of bipolar disorder, schizophrenia, multiple sclerosis (MS), Alzheimer disease, Parkinson disease, Huntington's disease, amyotrophic lateral sclerosis (ALS), and/or epilepsy by administrating formulations or compositions comprising an effective amount of endoxifen.Type: GrantFiled: September 16, 2020Date of Patent: June 13, 2023Assignee: JINA PHARMACEUTICALS, INC.Inventors: Ateeq Ahmad, Shoukath M. Ali, Moghis U. Ahmad, Saifuddin Sheikh, Imran Ahmad
-
Publication number: 20220347121Abstract: The invention relates to stable preparations of thymoquinone and methods of making and administering stable preparations of thymoquinone. Embodiments of the methods provide compositions comprising thymoquinone with phosphatidylcholine and/or guggulsterol and/or guggulsterol derivatives and/or sodium cholesteryl sulfate, in tablet, capsule, gel, or ointment forms, and method of administering the preparations.Type: ApplicationFiled: July 19, 2022Publication date: November 3, 2022Inventors: Shoukath M. ALI, Saifuddin SHEIKH, Ateeq AHMAD, Moghis U. AHMAD, Paul CHEN, Imran AHMAD
-
Patent number: 11389413Abstract: The invention relates to stable preparations of thymoquinone and methods of making and administering stable preparations of thymoquinone. Embodiments of the methods provide compositions comprising thymoquinone with phosphatidylcholine and/or guggulsterol and/or guggulsterol derivatives and/or sodium cholesteryl sulfate, in tablet, capsule, gel, or ointment forms, and method of administering the preparations.Type: GrantFiled: September 12, 2018Date of Patent: July 19, 2022Assignee: Jina Pharmaceuticals, Inc.Inventors: Shoukath M. Ali, Saifuddin Sheikh, Ateeq Ahmad, Moghis U. Ahmad, Paul Chen, Imran Ahmad
-
Patent number: 11291640Abstract: A method for maintaining a therapeutically effective concentration of endoxifen for the treatment of patient with bipolar I disorder is provided. The method includes administering to the patient a dose of 2 mg to 16 mg of endoxifen citrate in an enteric coated tablet once per day for at least 21 days. Further, the said method provides a desirable in-vivo plasma profile. The therapeutic dose monitoring is not required in a patient undergoing the said treatment. Furthermore, the method provides a significant improvement in mania assessed by the YMRS and the MADRS scores in patient undergoing the said treatment. Furthermore, the method as provides an early response time of the treatment in at least 2 days and remission time that is not more than 4 days in patient undergoing the said treatment.Type: GrantFiled: April 9, 2021Date of Patent: April 5, 2022Assignee: Jina Pharmaceuticals, Inc.Inventors: Ateeq Ahmad, Imran Ahmad, Moghisuddin Ahmad, Shoukath M Ali, Saifuddin Sheikh
-
Publication number: 20210322342Abstract: A method for managing or decreasing a risk of adverse effects in a patient undergoing treatment of bipolar I disorder is provided. The said method includes maintaining the therapeutically effective concentration of endoxifen by administrating a dose of 2 mg to 16 mg of endoxifen citrate in an enteric coated tablet once per day for at least 21 days. Further, adverse effects of alteration in thyroid functions, and thrombocytopenia can be avoided.Type: ApplicationFiled: April 9, 2021Publication date: October 21, 2021Inventors: Ateeq AHMAD, Imran AHMAD, Moghisuddin AHMAD, Shoukath M. ALI, Saifuddin SHEIKH
-
Publication number: 20210315844Abstract: A method for managing or decreasing a risk of suicidal behaviour in a patient undergoing treatment of bipolar I disorder is provided. The said method includes maintaining the therapeutically effective concentration of endoxifen by administrating a dose of 2 mg to 16 mg of endoxifen citrate in an enteric coated tablet once per day for at least 21 days.Type: ApplicationFiled: April 9, 2021Publication date: October 14, 2021Inventors: Ateeq AHMAD, Imran AHMAD, Moghisuddin AHMAD, Shoukath M. ALI, Saifuddin SHEIKH
-
Publication number: 20210315843Abstract: A method for maintaining a therapeutically effective concentration of endoxifen for the treatment of patient with bipolar I disorder is provided. The method includes administering to the patient a dose of 2 mg to 16 mg of endoxifen citrate in an enteric coated tablet once per day for at least 21 days. Further, the said method provides a desirable in-vivo plasma profile. The therapeutic dose monitoring is not required in a patient undergoing the said treatment. Furthermore, the method provides a significant improvement in mania assessed by the YMRS and the MADRS scores in patient undergoing the said treatment. Furthermore, the method as provides an early response time of the treatment in at least 2 days and remission time that is not more than 4 days in patient undergoing the said treatment.Type: ApplicationFiled: April 9, 2021Publication date: October 14, 2021Inventors: Ateeq AHMAD, Imran AHMAD, Moghisuddin AHMAD, Shoukath M ALI, Saifuddin SHEIKH
-
Publication number: 20210315845Abstract: A method for maintaining a therapeutically effective concentration of endoxifen for treatment of a patient with bipolar I disorder is provided. The said method includes administering to the patient, a dose of 2 mg to 16 mg of endoxifen citrate in an enteric coated tablet once per day for at least 21 days. Further, the patient is not required to be administered rescue medication during the administration of the endoxifen citrate.Type: ApplicationFiled: April 9, 2021Publication date: October 14, 2021Inventors: Ateeq AHMAD, Imran AHMAD, Moghisuddin AHMAD, Shoukath M ALI, Saifuddin SHEIKH
-
Publication number: 20210177752Abstract: The present invention provides compositions containing endoxifen, formulations and liposomes of endoxifen, methods of preparation of such agents and formulations, and use of such agents and formulations for the treatment of a subject having or at risk for psychiatric and neurodegenerative diseases. Specifically, the present invention relates to the composition comprising endoxifen in the treatment of bipolar disorder, schizophrenia, multiple sclerosis (MS), Alzheimer disease, Parkinson disease, Huntington's disease, amyotrophic lateral sclerosis (ALS), and/or epilepsy by administrating formulations or compositions comprising an effective amount of endoxifen.Type: ApplicationFiled: September 16, 2020Publication date: June 17, 2021Inventors: Ateeq Ahmad, Shoukath M. Ali, Moghis U. Ahmad, Saifuddin Sheikh, Imran Ahmad
-
Publication number: 20210008008Abstract: The invention relates to stable preparations of thymoquinone and methods of making and administering stable preparations of thymoquinone. Embodiments of the methods provide compositions comprising thymoquinone with phosphatidylcholine and/or guggulsterol and/or guggulsterol derivatives and/or sodium cholesteryl sulfate, in tablet, capsule, gel, or ointment forms, and method of administering the preparations.Type: ApplicationFiled: September 12, 2018Publication date: January 14, 2021Applicant: Jina Pharmaceuticals, Inc.Inventors: Shoukath M. ALI, Saifuddin SHEIKH, Ateeq AHMAD, Moghis U. AHMAD, Paul CHEN, Imran AHMAD
-
Publication number: 20200345849Abstract: The present invention relates to a methods of preparing active compounds complexed with lipids using aqueous systems that are free of organic solvents, and methods of using the complexes, e.g., in treating a disease in a subject. In some embodiments, the present invention comprises a composition comprising a complex comprising at least one active compound, e.g., a polyene antibiotic, an immunosuppressant agent such as tacrolimus or a taxane or taxane derivative, and one or more lipids. In some embodiments, the present invention provides a method comprising preparing a composition comprising a lipid complex comprising at least one active compound and at least one lipid and administering the composition to a subject. In certain embodiments the subject is a mammal. In certain preferred embodiments, the subject is human.Type: ApplicationFiled: July 9, 2020Publication date: November 5, 2020Applicants: JINA PHARMACEUTICALS, INC., JINA PHARMACEUTICALS, INC.Inventors: Shoukath M. Ali, Moghis U. Ahmad, Ateeq Ahmad, Saifuddin Sheikh, Imran Ahmad
-
Patent number: 10376479Abstract: The present invention provides compositions containing endoxifen, formulations and liposomes of endoxifen, methods of preparation of such agents and formulations, and use of such agents and formulations for the treatment of breast cancer and other breast diseases and diseases susceptible to endoxifen. In particular, the compositions of the present invention include liposomes, complexes, vesicles, emulsions, micelles and mixed micelles of endoxifen in which the compositions further contain any of a variety of neutral or charged lipids and desirably, cholesterol and cholesterol derivatives, sterols, Z- and E-guggulsterones, phospholipids, fatty acids, vitamin D, and vitamin E. The present invention also provides methods of preparing endoxifen. The present invention provides methods for treating and preventing breast cancer and other breast related diseases by administrating novel formulations or compositions comprising a therapeutically effective amount of endoxifen.Type: GrantFiled: April 27, 2016Date of Patent: August 13, 2019Assignee: Jina Pharmaceuticals, Inc.Inventors: Ateeq Ahmad, Shoukath M. Ali, Moghis U. Ahmad, Saifuddin Sheikh, Imran Ahmad
-
Publication number: 20190231687Abstract: The present invention provides compositions containing endoxifen, formulations and liposomes of endoxifen, methods of preparation of such agents and formulations, and use of such agents and formulations for the treatment of a subject having or at risk for psychiatric and neurodegenerative diseases. Specifically, the present invention relates to the composition comprising endoxifen in the treatment of bipolar disorder, schizophrenia, multiple sclerosis (MS), Alzheimer disease, Parkinson disease, Huntington's disease, amyotrophic lateral sclerosis (ALS), and/or epilepsy by administrating formulations or compositions comprising an effective amount of endoxifen.Type: ApplicationFiled: April 5, 2019Publication date: August 1, 2019Inventors: Ateeq Ahmad, Shoukath M. Ali, Moghis U. Ahmad, Saifuddin Sheikh, Imran Ahmad
-
Patent number: 9750812Abstract: The present invention relates to the topical and oral delivery of a composition comprising one or more active agents for treating a disease or symptoms in a subject. In some embodiments, the present invention comprises a composition comprising at least one active compound, e.g., finasteride or minoxidil, and one or more lipids. In some embodiments, the present invention relates to composition and method of preparation for treating androgenic alopecia (AGA), prevention of hair loss and female hirsutism. In some embodiment, the present invention comprises finasteride and at least one lipid component for the treatment of benign prostatic hyperplasia. In some embodiment, the present invention comprises tacrolimus or amphotericin B and at least one lipid component for the treatment of skin or eye related diseases.Type: GrantFiled: September 25, 2009Date of Patent: September 5, 2017Assignee: JINA PHARMACEUTICALS, INC.Inventors: Shoukath M. Ali, Ateeq Ahmad, Moghis U. Ahmad, Saifuddin Sheikh, Imran Ahmad
-
Publication number: 20170210775Abstract: The present invention relates to the methods for preparing synthetic guggulphospholipids, their fatty acid analogues and other bioactive molecules. The present invention relates to E-guggulsterone and Z-guggulsterone or mixture of E- and Z-guggulsterones, and E-guggulsterol and Z-guggulsterol or mixture of E- and Z-guggulsterols synthetically modified to guggulphospholipids and analogues and salts thereof, fatty acid analogues of guggulsterols, guggulsulfate and salts thereof, guggulphosphate and salts thereof; and guggulsterols conjugated with drugs for use as prodrugs. Also the present invention provides a novel method for the preparation of E-guggulsterol and Z-guggulsterol or mixture of E- and Z-guggulsterols from a mixture of E- and Z-guggulsterones.Type: ApplicationFiled: April 10, 2017Publication date: July 27, 2017Inventors: Moghis U. Ahmad, Shoukath M. Ali, Ateeq Ahmad, Saifuddin Sheikh, Imran Ahmad
-
Patent number: 9637515Abstract: The present invention relates to the methods for preparing synthetic guggulphospholipids, their fatty acid analogues and other bioactive molecules. The present invention relates to E-guggulsterone and Z-guggulsterone or mixture of E- and Z-guggulsterones. The present invention also provides a novel method for the preparation of E-guggulsterol and Z-guggulsterol or mixture of E- and Z-guggulsterols from a mixture of E- and Z-guggulsterones. The present invention further relates to guggulphospholipids and other bioactive molecules incorporated into complexes such as liposomes, complexes, emulsions, vesicles, micelles, and mixed micelles, which can include other active agents, such as hydrophobic or hydrophilic drugs for use, e.g., in treatment of human and animal diseases.Type: GrantFiled: November 6, 2007Date of Patent: May 2, 2017Assignee: JINA PHARMACEUTICALS, INC.Inventors: Moghis U. Ahmad, Shoukath M. Ali, Ateeq Ahmad, Saifuddin Sheikh, Imran Ahmad
-
Publication number: 20160346230Abstract: The present invention provides compositions containing endoxifen, formulations and liposomes of endoxifen, methods of preparation of such agents and formulations, and use of such agents and formulations for the treatment of breast cancer and other breast diseases and diseases susceptible to endoxifen. In particular, the compositions of the present invention include liposomes, complexes, vesicles, emulsions, micelles and mixed micelles of endoxifen in which the compositions further contain any of a variety of neutral or charged lipids and desirably, cholesterol and cholesterol derivatives, sterols, Z- and E-guggulsterones, phospholipids, fatty acids, vitamin D, and vitamin E. The present invention also provides methods of preparing endoxifen. The present invention provides methods for treating and preventing breast cancer and other breast related diseases by administrating novel formulations or compositions comprising a therapeutically effective amount of endoxifen.Type: ApplicationFiled: April 27, 2016Publication date: December 1, 2016Inventors: Ateeq Ahmad, Shoukath M. Ali, Moghis U. Ahmad, Saifuddin Sheikh, Imran Ahmad
-
Publication number: 20160310600Abstract: The present invention relates to a methods of preparing active compounds complexed with lipids using aqueous systems that are free of organic solvents, and methods of using the complexes, e.g., in treating a disease in a subject. In some embodiments, the present invention comprises a composition comprising a complex comprising at least one active compound, e.g., a polyene antibiotic, an immunosuppressant agent such as tacrolimus or a taxane or taxane derivative, and one or more lipids. In some embodiments, the present invention provides a method comprising preparing a composition comprising a lipid complex comprising at least one active compound and at least one lipid and administering the composition to a subject. In certain embodiments the subject is a mammal. In certain preferred embodiments, the subject is human.Type: ApplicationFiled: July 7, 2016Publication date: October 27, 2016Inventors: Shoukath M. Ali, Moghis U. Ahmad, Ateeq Ahmad, Saifuddin Sheikh, Imran Ahmad
-
Patent number: 9333190Abstract: The present invention provides compositions containing endoxifen, formulations and liposomes of endoxifen, methods of preparation of such agents and formulations, and use of such agents and formulations for the treatment of breast cancer and other breast diseases and diseases susceptible to endoxifen. In particular, the compositions of the present invention include liposomes, complexes, vesicles, emulsions, micelles and mixed micelles of endoxifen in which the compositions further contain any of a variety of neutral or charged lipids and desirably, cholesterol and cholesterol derivatives, sterols, Z- and E-guggulsterones, phospholipids, fatty acids, vitamin D, and vitamin E. The present invention also provides methods of preparing endoxifen. The present invention provides methods for treating and preventing breast cancer and other breast related diseases by administrating novel formulations or compositions comprising a therapeutically effective amount of endoxifen.Type: GrantFiled: November 21, 2007Date of Patent: May 10, 2016Assignee: JINA PHARMACEUTICALS, INC.Inventors: Ateeq Ahmad, Shoukath M. Ali, Moghis U. Ahmad, Saifuddin Sheikh, Imran Ahmad